Novel anti-tubulin cytotoxic agents for breast cancer

Expert Review of Anticancer Therapy

Volumn 9, Issue 2, 2009, Pages 175-185

  Morris, Patrick G ^a   Fornier, Monica N ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

ABI 007; Breast cancer; Epothilone; Eribulin; Larotaxel; Paclitaxel poliglumex; Taxane resistance; Trastuzumab MCC DM1; Vinflunine

Indexed keywords

21 AMINOEPOTHILONE B; 9,10 DIDEHYDROEPOTHILONE D; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CAPECITABINE; CISPLATIN; CORTICOSTEROID; CYTOTOXIC AGENT; DM1; DOCETAXEL; DOXORUBICIN; EPOTHILONE B; EPOTHILONE D; EPOTHILONE DERIVATIVE; ERIBULIN; GEMCITABINE; IXABEPILONE; LAROTAXEL; MAYTANSINE; NANOPARTICLE; NAVELBINE; PACLITAXEL; PACLITAXEL POLIGLUMEX; RPR 109881A; SAGOPILONE; SORAFENIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VASCULOTROPIN; VINCA ALKALOID; VINFLUNINE; 2 (3 AMINO 2 HYDROXYPROPYL)HEXACOSAHYDRO 3 METHOXY 26 METHYL 20,27 BIS(METHYLENE)11,15 18,21 24,28 TRIEPOXY 7,9 ETHANO 12,15 METHANO 9H,15H FURO(3,2 I)FURO(2',3' 5,6)PYRANO(4,3 B)(1,4)DIOXACYCLOPENTACOSIN 5 (4H) ONE; 2-(3-AMINO-2-HYDROXYPROPYL)HEXACOSAHYDRO-3-METHOXY-26-METHYL-20,27-BIS(METHYLENE)11,15-18,21-24,28-TRIEPOXY-7,9-ETHANO-12,15-METHANO-9H,15H-FURO(3,2-I)FURO(2',3'-5,6)PYRANO(4,3-B)(1,4)DIOXACYCLOPENTACOSIN-5-(4H)-ONE; ALBUMIN BOUND PACLITAXEL; ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; KETONE; TAXOID; TUBULIN MODULATOR;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLADDER CANCER; BLOOD TOXICITY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SCREENING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; ILEUS; INFECTION; INJECTION SITE REACTION; KERATITIS; LEUKOPENIA; MAXIMUM TOLERATED DOSE; METASTASIS POTENTIAL; MICROTUBULE ASSEMBLY; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; PROTEIN TARGETING; RECOMMENDED DRUG DOSE; REVIEW; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SIDE EFFECT; SOLID TUMOR; STOMATITIS; TUMOR GROWTH; VOMITING; BREAST TUMOR; FEMALE; PATHOPHYSIOLOGY;

ALBUMINS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; EPOTHILONES; FEMALE; FURANS; HUMANS; KETONES; NANOPARTICLES; PACLITAXEL; TAXOIDS; TUBULIN MODULATORS; VINCA ALKALOIDS;

EID: 64349105859     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.9.2.175     Document Type: Review

References (70)

1. Stewart BW KP. World Cancer Report. IARC Press, Lyon, France (2003).
2. Joensuu H, Kellokumpu-Lehtinen PL, Bono P et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N. Engl. J. Med. 354, 809-20 (2006).
3. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353, 1673-1684 (2005).
4. Slamon D, Eiermann W, Robert N et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presented at: 28th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 8-11 December 2005 (Abstract 1).
5. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344, 783-792 (2001).
6. Atzori F, Fornier M. Epothilones in breast cancer: current status and future directions. Expert Rev. Anticancer Ther. 8(8), 1299-1311 (2008).
7. Gerth K, Bedorf N, Hofle G et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J. Antibiot. (Tokyo) 4(9), 560-563 (1996).
8. Nettles JH, Li H, Cornett B et al. The binding mode of epothilone A on α,β-tubulin by electron crystallography. Science 30(5), 866-869 (2004).
9. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J. Clin. Oncol. 2(5), 5210-5217 (2007).
10. Nyman DW, Campbell KJ, Hersh E et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J. Clin. Oncol. 2(3), 7785-7793 (2005).
11. Desai N, Trieu V, Yao Z et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin. Cancer Res. 1(2), 1317-1324 (2006).
12. Ibrahim NK, Desai N, Legha S et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilised, nanoparticle formulation of paclitaxel. Clin. Cancer Res. 8, 1038-1044 (2002).
13. Ibrahim NK, Samuels B, Page R et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J. Clin. Oncol. 2(3), 6019-6026 (2005).
14. Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J. Clin. Oncol. 2(3), 7794-803 (2005).
15. Gradishar W, Krasnojon D, Cheporov S et al. Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared with q3w docetaxel as first-line therapy in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 25(Suppl. 8), (2007) (Abstract 1032).
16. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J. Clin. Oncol. 2(6), 3950-3957 (2008).
17. Roy V, LaPlant B, Gross G et al. NCCTG Phase II trial N0531of weekly nab-paclitaxel in combination with gemcitabine in patients with metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 25, (2007) (Abstract 1048).
18. Seidman A, Conlin A, Bach A et al. Phase II study of weekly nanoparticle albumin bound (nab)paclitaxel with carboplatin and trastuzumab as 1st-line therapy for HER2-positive metastatic breast cancer (MBC). ASCO Meeting Abstracts 26, (2008) (Abstract 1047).
19. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 35(7), 2666-2676 (2007).
20. Miles D, Chan A, Romieu G. Randomized, double-blind, placebo-controlled, Phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO. J. Clin. Oncol. ASCO Ann. Meeting Proc. 26, LBA1011 (2008).
21. Seidman AD, Berry D, Cirrincione C et al. Randomized Phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J. Clin. Oncol. 2(6), 1642-1649 (2008).
22. Citron ML, Berry DA, Cirrincione C et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 2(1), 1431-1439 (2003).
23. Khan M, Sharef S, Amato R. Phase II study of xyotax (PPX) for androgen independent prostate cancer Proc. Am. Soc. Clin. Oncol. 24, (2006) (Abstract 14624).
24. Nemunaitis J, Leighl N, Miller W et al. Paclitaxel poliglumex in combination with carboplatin for the first-line treatment of patients with advanced non-small cell lung cancer: preliminary data. Proc. Am. Soc. Clin. Oncol. 23, (2005) (Abstract 7230).
25. Sabbatini P, Aghajanian C, Dizon D et al. Phase II study of CT-2103 in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma. J. Clin. Oncol. 2(2), 4523-4531 (2004).
26. Lin NU, Parker LM, Come SE et al. Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest. New Drugs 2(5), 369-375 (2007).
27. Northfelt D, Allred J, Liu H et al. Phase II trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 26, (2008) (Abstract 1063).
28. Bissery MC: Preclinical evaluation of new taxoids. Curr. Pharm. Des. 7, 1251-1257 (2001).
29. Bissery M-C, Vrignaud P, Combeau C et al. Preclinical evaluation of XRP9881A, a new taxoid. Proc. Am. Assoc. Cancer Res. 45, (2004) (Abstract 5430).
30. Vrignaud P, Lejeune P, Bissery M-C. In vivo synergy between doxorubicin, cisplatin or vinorelbine and RPR 109881A, a new taxoid. Proc. Am. Assoc. Cancer Res. 46, (2005) (Abstract 3414).
31. Kurata T, Shimada Y, Tamura T et al. Phase I and pharmacokinetic study of a new taxoid, RPR 109881A, given as a 1-hour intravenous infusion in patients with advanced solid tumors. J. Clin. Oncol. 1(8), 3164-3171 (2000).
32. Sessa C, Cuvier C, Caldiera S et al. Phase I clinical and pharmacokinetic studies of the taxoid derivative RPR 109881A administered as a 1-hour or a 3-hour infusion in patients with advanced solid tumors. Ann. Oncol. 1(3), 1140-1150 (2002).
33. Gelmon KA, Latreille J, Tolcher A et al. Phase I dose-finding study of a new taxane, RPR 109881A, administered as a one-hour intravenous infusion days 1 and 8 to patients with advanced solid tumors. J. Clin. Oncol. 1 8, 4098-108 (2000).
34. Dieras V, Limentani S, Romieu G et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. Ann. Oncol. 1(9), 1255-1260 (2008).
35. Vrignaud P, Chiron M, Stackhouse M et al. In vivo synergy between trastuzumab (Herceptin®) and larotaxel (RPR 109881A), a new taxoid. Proc. Am. Assoc. Cancer Res. (2007) (Abstract 1432).
36. Zatloukal P, Gervais R, Vansteenkiste J et al. Randomized multicenter Phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as first-line chemotherapy in nonirradiable stage IIIB or stage IV non-small cell lung cancer. J. Thorac. Oncol. 3, 894-901 (2008).
37. Etievant C, Barret JM, Kruczynski A et al. Vinflunine (20é, 20é-difluoro-3é, 4é-dihydrovinorelbine), a novel Vinca alkaloid, which participates in P-glycoprotein (Pgp)-mediated multidrug resistance in vivo and in vitro. Invest. New Drugs 1(6), 3-17 (1998).
38. Etievant C, Kruczynski A, Barret JM et al. Markedly diminished drug resistanceinducing properties of vinflunine (20′, 20′-difluoro-3′, 4′-dihydrovinorelbine) relative to vinorelbine, identified in murine and human tumor cells in vivo and in vitro. Cancer Chemother. Pharmacol. 4(8), 62-70 (2001).
39. Lobert S, Ingram JW, Hill BT et al. A comparison of thermodynamic parameters for vinorelbine- and vinflunine-induced tubulin self-association by sedimentation velocity. Mol. Pharmacol. 5(3), 908-915 (1998).
40. Kruczynski A, Colpaert F, Tarayre JP et al. Preclinical in vivo antitumor activity of vinflunine, a novel fluorinated vinca alkaloid. Cancer Chemother. Pharmacol. 4(1), 437-447 (1998).
41. Bennouna J, Fumoleau P, Armand JP et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumors. Ann. Oncol. 1(4), 630-637 (2003).
42. Johnson P, Geldart T, Fumoleau P et al. Phase I study of vinflunine administered as a 10-min infusion on days 1 and 8 every 3 weeks. Invest. New Drugs 2(4), 223-231 (2006).
43. Culine S, Theodore C, De Santis M et al. A Phase II study of vinflunine in bladder cancer patients progressing after first-line platinum-containing regimen. Br. J. Cancer 9(4), 1395-1401 (2006).
44. Bennouna J, Breton JL, Tourani JM et al. Vinflunine - an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a Phase II study. Br. J. Cancer 9(4), 1383-1388 (2006).
45. Talbot DC, Margery J, Dabouis G et al. Phase II study of vinflunine in malignant pleural mesothelioma. J. Clin. Oncol. 2(5), 4751-4756 (2007).
46. Goldstein D, Ackland SP, Bell DR et al. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest. New Drugs 2(4), 429-434 (2006).
47. Olver IN, Byrne MJ, Walpole E et al. Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma. Eur. J. Cancer 4(3), 1829-1832 (2007).
48. Campone M, Cortes-Funes H, Vorobiof D et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a Phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br. J. Cancer 9(5), 1161-1166 (2006).
49. Campone M, Fumoleau P, Roche H et al. A dose-finding and pharmacokinetic study of I.V. vinflunine in combination with capecitabine as second line treatment of metastatic breast cancer. Presented at: 29th San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 14-17 December 2006 (Abstract 6069).
50. Paridaens R, Wildiers H, Dalenc F et al. Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 25, (2007) (Abstract 1058).
51. Peacock N, Spigel D, Mainwaring M et al. Preliminary results of a multicenter Phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 25, (2007) (Abstract 1043).
52. Jordan MA, Kamath K, Manna T et al. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol. Cancer Ther. 4, 1086-1095 (2005).
53. Morris PG, Fornier MN. Microtubule active agents: beyond the taxane frontier. Clin. Cancer Res. 1(4), 7167-7172 (2008).
54. Kuznetsov G, Towle MJ, Cheng H et al. Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389. Cancer Res. 6(4), 5760-5766 (2004).
55. Towle MJ, Salvato KA, Budrow J et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 6(1), 1013-1021 (2001).
56. Desai K, Goel S, Mita A et al. Dose escalation and pharmacokinetic study of E 7389, a microtubule-binding drug in patients with advanced solid tumors Proc. Am. Soc. Clin. Oncol. 23, (2005) (Abstract 3090).
57. Synold T, Morgan R, Newman E et al. A Phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. Proc. Am. Soc. Clin. Oncol. 16, (2005) (Abstract 3036).
58. Rubin E, Rosen L, Rajeev V et al. Phase I study of E7389 administered by 1 hour infusion every 21 days Proc. Am. Soc. Clin. Oncol. 23, (2005) (Abstract 2054).
59. Vahdat L, Twelves C, Allison M et al. Phase II study of eribulin mesylate (E7389) in patients with locally advanced or metastatic breast cancer previously treated with anthracycline, taxane, and capecitabine therapy. Proc. Am. Soc. Clin. Oncol. 15S, (2008) (Abstract 1084).
60. Beeram M, A. Burris H, Modi S et al. A Phase I study of trastuzumab-DM1 (T-DM1), a first-in-class HER2 antibodydrug conjugate (ADC), in patients (pts) with advanced HER2+ breast cancer (BC). ASCO Meeting Abstracts (2008) (Abstract 1028).
61. Holden S, Beeram M, Krop I et al. A Phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC). ASCO Meeting Abstracts (2008) (Abstract 1029).
62. Issell BF, Crooke ST. Maytansine. Cancer Treat. Rev. 5, 199-207 (1978).
63. Conlin A, Seidman A, Moynahan M et al. Randomized Phase II trial of three dosing schedules of nanoparticle albumin-bound paclitaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer: an initial interim safety report. ASCO Meeting Abstracts 25, (2007) (Abstract 1104).
64. Gluck S, Lobo C, Reis I et al. Phase II study of nab-paclitaxel, bevacizumab, and gemcitabine for first-line therapy of patients with HER2-negative metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 26, (2008) (Abstract 1089).
65. Danso M, Blum J, Robert N et al. Phase II trial of weekly nab-paclitaxel in combination with bevacizumab as first-line treatment in metastatic breast cancer. Proc. Am. Soc. Clin. Oncol. 26, (2008) (Abstract 1075).
66. Burstein H, Mayer E, Peppercorn J et al. Dose-dense nab-paclitaxel (nanoparticle albumin-bound paclitaxel) in adjuvant chemotherapy for breast cancer: a feasibility study. Proc. Am. Soc. Clin. Oncol. 25, (2007) (Abstract 594).
67. McArthur H, Rugo H, Paulson M et al. Cardiac safety of adjuvant bevacizumab plus dose-dense doxorubicin/cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Presented as: San Antonio Breast Cancer Symposium. San Antonio, TX, USA, 13-16 December 2007 (Abstract 3065).
68. Morris P, Dickler M, McArthur H et al. Dose-dense doxorubicin-cyclophosphamide X 4 and short-term changes in left ventricular ejection fraction alone or with bevacizumab in patients with early stage breast cancer Proc. Am. Soc. Clin. Oncol. 26, (2008) (Abstract 637).
69. Sierecki M, Rugo H, McArthur H et al. Incidence and severity of sensory neuropathy with bevacizumab added to dose-dense doxorubicin/ cyclophosphamide followed by nanoparticle albumin-bound paclitaxel in patients with early stage breast cancer. Proc. Am. Soc. Clin. Oncol. 26, (2008) (Abstract 589).
70. Dieras V, Viens P, Veyret C et al. Larotaxel in combination with trastuzumab in patients with HER2 + metastatic breast cancer: interim analysis of an open Phase II label study. Proc. Am. Soc. Clin. Oncol. 26, (2008) (Abstract 1070).